Ranjit Bindra, MD
Enriched profileHarvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology · Yale School of Medicine
Ranjit Bindra is Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine. OpenAlex indexes 415 publications with 9,725 citations (h-index 44); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Ranjit Bindra, M.D., PH.D., is Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine. The public record shows 415 publications with 9,725 citations (h-index 44), centered on Glioma Diagnosis and Treatment, PARP inhibition in cancer therapy, DNA Repair Mechanisms. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 3 companies, 5 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Glioma Diagnosis and Treatment
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 85.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Co-founder
Cybrexa Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗ - Founder
Alphina Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗ - Founder
Modifi Bio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
Sponsor: Cavion, Inc.
Industry payments
Updated 16 Oct 2026
3 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments$20,583openpaymentsdata.cms.gov ↗
- Sage Therapeutics, LLCProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20243 payments$30,000openpaymentsdata.cms.gov ↗
NIH funding
Updated 16 Oct 2026
5 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Novel therapeutics for the targeted eradication of DDR-defective tumors
Yale University
FY2026$654,163R01CA276186 - Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML
Yale University
FY2026$585,107R01CA266604
Congress activity
Updated 16 Oct 2026
85 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, SABCS per OpenAlex. The most recent:
- Abstract 1749: Modeling response to alkylating chemotherapy in a syngeneic model of MGMT overexpression and MMR-deficient glioma
AACR Annual Meeting
AACR2026Co-author - Abstract B021: LIG1 deficiency increases sensitivity to NAMPT inhibitors in pediatric extracranial sarcomas
AACR (meeting unresolved)
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Targeting O6-methylguanine-DNA Methyltransferase Deficiency in Preclinical Models of Extracranial Human Cancers with a Tumor-Selective DNA-Modifying Agent.
Molecular cancer therapeutics
Article2026 - CellPyAbility: automated image analysis for high-throughput dose-response screening.
Bioinformatics (Oxford, England)
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type IIIArticle867 citations1997
- 03
- 04
- 05Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer CellsArticle356 citations2004
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ranjit-bindra-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Advisory Board Member
Yale Ventures
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗ - Board Member
amplifyHERScience
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗ - Faculty
AACR Molecular Biology in Clinical Oncology Workshop
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - Board Member
BioCT
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →businesswire.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ventures.yale.edu ↗
- Fellow
American Society for Clinical Investigation (ASCI)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- Professor of Neurosurgery
Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Co-Director
Chênevert Family Brain Tumor Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Vice Chair for Translational Research and Faculty Development
Therapeutic Radiology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Chief
Central Nervous System Radiotherapy Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harlan Krumholz, MD
Yale School of Medicine
Eric Winer, MD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine
Robert Rosenheck, MD
Yale School of Medicine
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
David Reardon, MD
Dana-Farber Cancer Institute